Autor: "Selzler KJ" - OpacWWW

Skocz do pozycji: 2.

Tytuł:: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
Autorzy:: Camporeale A; Eli Lilly Italia, Sesto Fiorentino, Italy.
Kudrow D; California Medical Clinic for Headache, Santa Monica, CA, USA.; UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Sides R; Eli Lilly and Company Corporate Center, Indianapolis, IN, 46285, USA.
Wang S; Eli Lilly and Company Corporate Center, Indianapolis, IN, 46285, USA.
Van Dycke A; Neurology Department, AZ Sint-Jan Brugge, Brugge, Belgium.
Selzler KJ; Eli Lilly and Company Corporate Center, Indianapolis, IN, 46285, USA.
Stauffer VL; Eli Lilly and Company Corporate Center, Indianapolis, IN, 46285, USA. .; Pokaż więcej
Źródło:: BMC neurology [BMC Neurol] 2018 Nov 09; Vol. 18 (1), pp. 188. Date of Electronic Publication: 2018 Nov 09.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal/*adverse effects
Antibodies, Monoclonal/*therapeutic use
Migraine Disorders/*drug therapy
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Young Adult

Czasopismo naukowe

Informacja